196 related articles for article (PubMed ID: 26287936)
1. SOX10 and Olig2 as negative markers for the diagnosis of ependymomas: An immunohistochemical study of 98 glial tumors.
Švajdler M; Rychlý B; Mezencev R; Fröhlichová L; Bednárová A; Pataky F; Daum O
Histol Histopathol; 2016 Jan; 31(1):95-102. PubMed ID: 26287936
[TBL] [Abstract][Full Text] [Related]
2. Olig2 and CD99 are useful negative markers for the diagnosis of brain tumors.
Ishizawa K; Komori T; Shimada S; Hirose T
Clin Neuropathol; 2008; 27(3):118-28. PubMed ID: 18552083
[TBL] [Abstract][Full Text] [Related]
3. SOX10 Distinguishes Pilocytic and Pilomyxoid Astrocytomas From Ependymomas but Shows No Differences in Expression Level in Ependymomas From Infants Versus Older Children or Among Molecular Subgroups.
Kleinschmidt-DeMasters BK; Donson AM; Richmond AM; Pekmezci M; Tihan T; Foreman NK
J Neuropathol Exp Neurol; 2016 Apr; 75(4):295-8. PubMed ID: 26945037
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity and specificity of epithelial membrane antigen staining patterns in ependymomas.
Hasselblatt M; Paulus W
Acta Neuropathol; 2003 Oct; 106(4):385-8. PubMed ID: 12898159
[TBL] [Abstract][Full Text] [Related]
5. Utility of combining OLIG2 and SOX10 IHC expression in CNS tumours: promising biomarkers for subtyping paediatric- and adult-type gliomas.
Aboubakr O; Métais A; Maillard J; Hasty L; Brigot E; Berthaud C; Lacombe J; Pucelle N; Raynal J; Appay R; Varlet P; Tauziède-Espariat A
Histopathology; 2024 Apr; 84(5):893-899. PubMed ID: 38253970
[TBL] [Abstract][Full Text] [Related]
6. The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas.
Ligon KL; Alberta JA; Kho AT; Weiss J; Kwaan MR; Nutt CL; Louis DN; Stiles CD; Rowitch DH
J Neuropathol Exp Neurol; 2004 May; 63(5):499-509. PubMed ID: 15198128
[TBL] [Abstract][Full Text] [Related]
7. OLIG2 is differentially expressed in pediatric astrocytic and in ependymal neoplasms.
Otero JJ; Rowitch D; Vandenberg S
J Neurooncol; 2011 Sep; 104(2):423-38. PubMed ID: 21193945
[TBL] [Abstract][Full Text] [Related]
8. Shared oligodendrocyte lineage gene expression in gliomas and oligodendrocyte progenitor cells.
Bouvier C; Bartoli C; Aguirre-Cruz L; Virard I; Colin C; Fernandez C; Gouvernet J; Figarella-Branger D
J Neurosurg; 2003 Aug; 99(2):344-50. PubMed ID: 12924709
[TBL] [Abstract][Full Text] [Related]
9. Oligodendroglial-specific transcriptional factor SOX10 is ubiquitously expressed in human gliomas.
Bannykh SI; Stolt CC; Kim J; Perry A; Wegner M
J Neurooncol; 2006 Jan; 76(2):115-27. PubMed ID: 16205963
[TBL] [Abstract][Full Text] [Related]
10. OLIG2 is a useful immunohistochemical marker in differential diagnosis of clear cell primary CNS neoplasms.
Preusser M; Budka H; Rössler K; Hainfellner JA
Histopathology; 2007 Feb; 50(3):365-70. PubMed ID: 17257132
[TBL] [Abstract][Full Text] [Related]
11. Predominant expression of OLIG2 over ID2 in oligodendroglial tumors.
Mikami S; Hirose Y; Yoshida K; Kawase T; Ohnishi A; Nagashima K; Mukai M; Okada Y; Ikeda E
Virchows Arch; 2007 May; 450(5):575-84. PubMed ID: 17431671
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical study of CD99 and EMA expression in ependymomas.
Mahfouz S; Aziz AA; Gabal SM; el-Sheikh S
Medscape J Med; 2008 Feb; 10(2):41. PubMed ID: 18382710
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical expression of Olig2, CD99, and EMA to differentiate oligodendroglial-like neoplasms.
Kurdi M; Eberhart C
Folia Neuropathol; 2021; 59(3):284-290. PubMed ID: 34628794
[TBL] [Abstract][Full Text] [Related]
14. Olig2-positive cells in glioneuronal tumors show both glial and neuronal characters: the implication of a common progenitor cell?
Matsumura N; Yokoo H; Mao Y; Yin W; Nakazato Y
Neuropathology; 2013 Jun; 33(3):246-55. PubMed ID: 23025580
[TBL] [Abstract][Full Text] [Related]
15. Gain of Olig2 function in oligodendrocyte progenitors promotes remyelination.
Wegener A; Deboux C; Bachelin C; Frah M; Kerninon C; Seilhean D; Weider M; Wegner M; Nait-Oumesmar B
Brain; 2015 Jan; 138(Pt 1):120-35. PubMed ID: 25564492
[TBL] [Abstract][Full Text] [Related]
16. Ezrin immunoreactivity is associated with increasing malignancy of astrocytic tumors but is absent in oligodendrogliomas.
Geiger KD; Stoldt P; Schlote W; Derouiche A
Am J Pathol; 2000 Dec; 157(6):1785-93. PubMed ID: 11106550
[TBL] [Abstract][Full Text] [Related]
17. Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2.
Rousseau A; Nutt CL; Betensky RA; Iafrate AJ; Han M; Ligon KL; Rowitch DH; Louis DN
J Neuropathol Exp Neurol; 2006 Dec; 65(12):1149-56. PubMed ID: 17146289
[TBL] [Abstract][Full Text] [Related]
18. Sox10 and S100 in the diagnosis of soft-tissue neoplasms.
Karamchandani JR; Nielsen TO; van de Rijn M; West RB
Appl Immunohistochem Mol Morphol; 2012 Oct; 20(5):445-50. PubMed ID: 22495377
[TBL] [Abstract][Full Text] [Related]
19. Immunolocalization of the oligodendrocyte transcription factor 1 (Olig1) in brain tumors.
Azzarelli B; Miravalle L; Vidal R
J Neuropathol Exp Neurol; 2004 Feb; 63(2):170-9. PubMed ID: 14989603
[TBL] [Abstract][Full Text] [Related]
20. Relevance of combinatorial profiles of intermediate filaments and transcription factors for glioma histogenesis.
Colin C; Virard I; Baeza N; Tchoghandjian A; Fernandez C; Bouvier C; Calisti A; Tong S; Durbec P; Figarella-Branger D
Neuropathol Appl Neurobiol; 2007 Aug; 33(4):431-9. PubMed ID: 17442061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
